Private and Confidential Addiction Treatment With Long-Acting Naltrexone: What Patients Should Know
DeBinge opioid transition: When travelling to DeBinge in The Bahamas for OLANI treatment, there is no requirement to complete a separate opioid-free waiting window before arrival. DeBinge uses a medically supervised 4-to-5-day buprenorphine transition. Buprenorphine is introduced to bridge the patient away from full-agonist opioids, stabilised and tapered over the first several days, and the O’Neil Long-Acting Naltrexone Implant is typically inserted around day 4 or 5 while buprenorphine is still being tapered. The planned overlap continues as buprenorphine clears and the implant gradually releases naltrexone. This pathway is clinician-supervised because mistimed naltrexone exposure can precipitate withdrawal.
Based on DeBinge’s clinical experience in The Bahamas since 2018, the implant typically provides its strongest craving and relapse-prevention support on average 9 months, while clinically meaningful opioid-receptor blockade may persist for longer, in some patients up to about 15 months. This longer blockade may continue to reduce opioid effects and overdose risk.
Ongoing recovery: The implant is not a cure. The DeBinge programme includes a full year of professional counselling after implantation to address the behavioural and psychological side of addiction.
Private addiction treatment can reduce unnecessary exposure of sensitive health information, but “private,” “confidential,” “discreet” and “anonymous” do not mean the same thing. Responsible medical treatment normally requires an identifiable patient record, appropriate clinical documentation and limited information sharing when it is necessary for safe care.
For someone considering long-acting naltrexone treatment abroad, privacy planning should therefore cover much more than choosing a quiet treatment setting. Patients should understand how records are stored, who can access them, when information can be shared, how family communication works, how counselling confidentiality is handled and what happens if an emergency requires communication with another healthcare professional.
DeBinge implant-based treatment takes place in Nassau, The Bahamas. DeBinge does not operate naltrexone implant clinics in Miami, Atlanta, Charlotte or other U.S. cities. Naltrexone implant formulations are not FDA-approved for clinical use in the United States. Patients in the U.S. can discuss FDA-approved oral naltrexone and extended-release injectable naltrexone options with local clinicians.
Can Addiction Treatment Be Private and Confidential?
Yes. Addiction treatment can be provided with substantial privacy and medical confidentiality, but a responsible treatment provider should not promise absolute anonymity.
A healthcare professional normally needs enough identifying and medical information to assess a patient safely, obtain valid consent, document care, prescribe or administer medication where appropriate, respond to emergencies and maintain continuity of care.
The most useful question is therefore not simply, “Can nobody ever know?” A better question is:
“Who will have access to my information, what information will they receive, why might they need it and what protections exist around disclosure?”
Patients considering treatment outside their home country should understand these points before sending medical records, booking travel or assuming that treatment abroad automatically makes care anonymous.
Privacy, Confidentiality, Discretion and Anonymity Are Different
Privacy
Privacy concerns limiting unnecessary access to personal information, physical space and details of treatment. Examples include private consultations, restricted medical-record access and avoiding unnecessary disclosure to third parties.
Medical Confidentiality
Medical confidentiality is the professional obligation to protect information learned during healthcare. It does not mean that information can never be shared. Disclosure may occur with patient consent or where applicable law, safeguarding requirements or urgent clinical safety justifies it.
Discretion
Discretion describes practical steps taken to reduce unnecessary visibility. This may include discreet communication, private scheduling, limited administrative exposure and avoiding unnecessary discussion of the reason for treatment.
Anonymity
True anonymity means that a person’s identity is unknown. That is generally incompatible with comprehensive medical treatment because clinicians need an identifiable medical history, consent record, medication information and appropriate clinical documentation.
A responsible medical service should explain what records it creates, who can access them and what confidentiality protections apply rather than suggesting that medically necessary documentation does not exist.
Why Do Some Patients Seek Discreet Addiction Treatment?
People seek greater privacy for many reasons. A patient may be a business owner, healthcare professional, executive, public-facing individual, parent or someone who simply considers addiction treatment deeply personal.
Common concerns include whether an employer could learn about treatment, whether family members will be contacted, whether insurance records identify the type of healthcare received, whether colleagues could recognize a treatment setting, how electronic communication is handled and how counselling records are stored.
These concerns are legitimate. They should be addressed through clear privacy procedures rather than unrealistic assurances that treatment creates no record or can never become known under any circumstances.
What Medical Information May Be Needed?
Long-acting naltrexone treatment requires enough information for clinicians to determine whether the treatment is appropriate and safe.
Depending on the individual, clinicians may need information about:
- substances currently or recently used;
- prescription medications;
- methadone or buprenorphine treatment;
- previous withdrawal experiences;
- previous addiction treatment;
- medical and psychiatric history;
- allergies and relevant medical conditions;
- relevant laboratory or toxicology information;
- emergency contacts where clinically appropriate;
- information relevant to future pain treatment or surgery.
Patients should ask how this information is collected, where records are stored, which staff members can access them and how long records are retained.
Where treatment occurs outside the United States, patients should not automatically assume that U.S. healthcare privacy rules apply in exactly the same way. The provider should explain which laws and professional confidentiality requirements apply to the location where treatment is delivered.
When Can Medical Information Be Shared?
In routine care, health information should generally be shared only for legitimate clinical, operational or legally permitted reasons according to the rules that apply to the provider and jurisdiction.
Sharing information with your home doctor
Some patients want their primary-care physician or addiction specialist to receive a treatment summary. Others prefer information to be shared only when clinically necessary. Discuss this before treatment so there is a clear plan for continuity of care.
Sharing information with family
Family involvement can be helpful, but being a relative does not automatically mean that a person should receive private medical information. Ask what consent is required before a partner, parent, sibling or other family member receives updates.
Emergency disclosure
An emergency can change normal information-sharing boundaries. If a patient becomes unconscious, severely unwell or needs urgent hospital care, relevant information may need to be communicated to another healthcare professional to protect that person’s safety.
A provider should protect patients from unnecessary disclosure while ensuring that essential medical information can reach emergency or follow-up clinicians when legitimately required.
Can Family Members Be Kept Outside the Treatment Process?
Adults generally have an important role in deciding who is involved in their care, subject to applicable law and safety requirements.
A patient who does not want routine information shared with relatives should communicate that clearly and ask the provider to document those preferences.
At the same time, some patients choose to involve a partner, parent, sibling or trusted friend because that person can assist with travel, recovery support, medication information or emergency planning.
Questions About Family
- Will family members be contacted automatically?
- Can I specify who may receive updates?
- What information could be shared in an emergency?
- Can I change my communication preferences?
Recovery Planning
- Who will support me when I return home?
- Who should know that long-acting naltrexone is active?
- Who should understand overdose and naloxone planning?
- Who can help if opioid use returns?
What About Employers, Professional Licensing and Reputation?
Patients often ask whether an employer will be informed that they are receiving addiction treatment. A treatment provider should explain its own disclosure practices, but employment, occupational-health and professional-licensing rules can vary according to country, occupation and circumstances.
People working in safety-sensitive professions may also have separate responsibilities relating to medications, impairment, fitness for work or professional regulation.
It would therefore be inappropriate for any clinic to promise that treatment can never have implications for employment or professional licensing. The safer approach is to understand what information the clinic itself controls and obtain independent occupational or legal advice where necessary.
If work involves professional driving, aviation, heavy machinery, clinical responsibility or another regulated safety-sensitive role, separate occupational requirements may apply.
How Does Medical Privacy Change When Treatment Happens Abroad?
Receiving treatment internationally creates an additional layer of privacy questions because healthcare regulation, data protection and medical-record requirements differ between countries.
A U.S. patient should not assume that every international provider operates under the same rules as a U.S. hospital or physician.
Before treatment, consider asking:
- Which country’s laws govern the clinical service?
- Where are electronic records stored?
- Who can access those records?
- How are electronic communications protected?
- How can records be transferred to my home clinician?
- What happens if I require emergency hospital treatment abroad?
- How long are medical records retained?
DeBinge implant-based treatment takes place in Nassau. For more information about the treatment location and U.S. regulatory status, read our guide to naltrexone implant availability in the United States and treatment in The Bahamas.
Confidential Consultation Before Making a Travel Decision
International treatment should normally begin with information gathering and medical discussion rather than an immediate travel booking.
A confidential consultation before travel can help clarify:
- what substance-use information is required;
- whether the patient may still be physically dependent on opioids;
- whether methadone, buprenorphine or another opioid medication is being used;
- whether additional medical assessment is required;
- which records should be provided;
- what privacy arrangements apply;
- how treatment in Nassau is organized;
- whether international treatment may be medically appropriate.
Telephone or video contact before travel should not be interpreted as a guarantee that implantation will take place. A final clinical decision may depend on further assessment, examination, testing or the patient’s condition closer to the procedure.
What Does Discreet Treatment Travel Actually Mean?
Discreet travel does not require creating a false story about medical care. It generally means minimizing unnecessary disclosure while keeping essential information available to people who genuinely need it.
Communication
Ask how appointment reminders, invoices, emails and telephone messages are worded and which communication method you prefer.
Travel Information
Ask what medical information should be carried and whether documentation explaining active naltrexone treatment is appropriate after the procedure.
Accommodation
Understand how accommodation and transport relate to the treatment plan and which information is shared with non-clinical service providers.
Patients should not sacrifice medical safety simply to make treatment less visible.
Private Medical Care Still Requires Clinical Structure
A private treatment environment should still include appropriate medical governance, assessment, consent, documentation, procedure standards and emergency planning.
Patients can learn more about the DeBinge treatment setting on the DeBinge clinic page for Nassau, The Bahamas.
The important distinction is between a quieter, more discreet environment and the idea that treatment happens outside normal clinical responsibilities. Privacy should reduce unnecessary exposure. It should not reduce medical standards.
How Does Long-Acting Naltrexone Fit Into Private Addiction Treatment?
Naltrexone is an opioid receptor antagonist. It binds to opioid receptors without activating them and can reduce or block opioid effects while sufficient antagonist concentrations are present.
A sustained-release implant is designed to release naltrexone for an extended period after placement beneath the skin. One practical rationale is adherence because the patient does not need to make a daily decision about taking a tablet.
However, the medication itself is not a privacy technology. An implant does not make treatment anonymous, eliminate the need for medical records or remove the need for counselling and follow-up.
Different implant formulations can also differ in dose, materials, release characteristics and evidence. Research involving one implant should not automatically be treated as evidence for another.
For a more detailed explanation, read our long-acting naltrexone implant guide.
Naltrexone implant formulations are not FDA-approved for clinical use in the United States. FDA-approved U.S. naltrexone options include appropriate oral formulations and extended-release injectable naltrexone.
Privacy Does Not Remove the Need for Medical Assessment
Someone seeking discreet treatment may understandably want to limit the number of people involved. However, naltrexone still requires clinically appropriate assessment.
For opioid use disorder, clinicians need to establish whether significant physical opioid dependence remains because starting naltrexone too early can precipitate severe withdrawal.
Fentanyl, methadone, buprenorphine and longer-acting opioids can complicate preparation. A responsible program should therefore avoid one-size-fits-all home detox schedules.
Patients should not be instructed to abruptly discontinue methadone or buprenorphine solely to make themselves eligible for an implant. Methadone and buprenorphine are established treatments for opioid use disorder, and any transition to antagonist treatment should be individually planned with an appropriate clinician.
Is Addiction Counselling Confidential?
Counselling often involves highly sensitive information about substance use, relationships, trauma, stress, mental health and personal circumstances. Patients should ask how counselling notes are handled and whether they are stored together with medical records or separately.
Useful questions include:
- Who can view counselling notes?
- Are summaries shared with the medical team?
- What information is routinely documented?
- What happens if the counsellor believes there is an immediate risk of serious harm?
- Can counselling continue remotely after the patient returns home?
- What privacy rules apply to counselling delivered across borders?
Confidentiality is important, but no responsible clinician should promise that every disclosure will remain secret in every possible circumstance. Serious safety, safeguarding or legal situations may create exceptions.
Follow-Up Requires Thoughtful Information Sharing
International treatment should not create a break in medical continuity when the patient returns home.
A useful discharge plan may include:
- a summary of treatment received;
- the date and type of long-acting naltrexone treatment;
- information relevant to emergency pain treatment;
- wound-care instructions where relevant;
- contact details for clinical questions;
- counselling arrangements;
- naloxone and overdose-safety planning;
- a plan for what happens when medication exposure declines.
Patients can maintain privacy from unnecessary third parties while still ensuring that clinicians involved in their future care have the information necessary to treat them safely.
12 Privacy Questions Worth Asking Any Addiction Treatment Provider
- What identifying information do you require before treatment?
- Where are medical records stored?
- Which staff members can access those records?
- Which privacy laws or professional confidentiality rules apply?
- Will family members be contacted without my permission?
- How do I authorize information sharing with another clinician?
- How are emails, calls and appointment reminders handled?
- How are counselling notes stored and shared?
- What information may need to be shared during an emergency?
- How can treatment records be transferred after I return home?
- What information should I carry about active naltrexone treatment?
- How long are records retained?
If you are comparing several implant providers, you can also use our 15-question framework for comparing long-acting naltrexone implant programs.
Private Treatment Planning With DeBinge
DeBinge implant-based treatment takes place in Nassau, The Bahamas. International treatment does not mean assessment, medical records or clinical documentation disappear.
The appropriate goal is professional discretion while collecting and sharing the information necessary for safe medical care.
A patient considering DeBinge should understand the clinical process, privacy arrangements, treatment location, long-acting naltrexone approach, preparation requirements, counselling arrangements and follow-up before making a travel decision.
Learn how a confidential consultation works before making a travel decision.
A consultation can be used to discuss treatment goals, current substance use, medications, privacy preferences, preparation requirements and the questions that should be answered before international care is considered.
Understand Treatment in The Bahamas Compare Implant ProgramsWhat Privacy and Treatment Questions Should You Ask Before Choosing a Program?
This educational tool does not decide whether a provider is suitable or sufficiently confidential. It helps identify privacy and treatment questions you may still need answered.
Your selections are processed only inside your browser and are not submitted to DeBinge.
Do you know what medical information the program will record and where those records are stored?
Do you know which staff members can access your medical and counselling information?
Have you discussed whether family members can receive treatment updates and what consent is required?
Do you understand which country’s privacy and healthcare rules apply where treatment will take place?
Have you asked how appointment reminders, telephone calls, emails and other communications are handled?
Do you understand what medical information must still be disclosed even when privacy is very important to you?
Do you know how counselling notes are stored and what information may be shared with the medical team?
Has the provider explained when medical information may need to be shared urgently for safety?
Do you know how treatment records can be transferred to your home clinician if follow-up is needed?
Your Privacy and Treatment Discussion Topics
These results do not rate a clinic and do not recommend treatment. They identify subjects you may want to clarify before choosing a program.
The aim is to reduce unnecessary disclosure while making sure clinicians have enough information to provide safe care and respond appropriately if an emergency occurs.
Private and Confidential Addiction Treatment FAQ
Can addiction treatment be completely anonymous?
Medical treatment normally requires an identifiable patient record, clinical history, consent and documentation. A provider can offer substantial privacy and discretion, but promising absolute anonymity may be unrealistic for comprehensive healthcare.
Will family members automatically be told about treatment?
Patients should discuss communication preferences and consent directly with the treatment provider. Family involvement should not simply be assumed, although exceptional clinical or legal circumstances can create a need for information sharing.
Will my employer be told?
A provider should explain its own disclosure practices. Employers are not automatically entitled to private medical information simply because someone receives addiction treatment, although occupational-health, professional-regulatory or safety-sensitive work requirements may apply separately.
Does treatment abroad guarantee greater privacy?
No. International treatment may provide geographic discretion, but medical records and clinical documentation remain necessary. Privacy and healthcare rules also vary by jurisdiction.
Is counselling confidential?
Counselling normally involves confidentiality protections, but patients should ask how notes are stored, who may access them and what exceptions apply when serious safety or legal concerns arise.
Are naltrexone implants FDA-approved in the United States?
No. Naltrexone implant formulations are not FDA-approved for clinical use in the United States. FDA-approved naltrexone options include appropriate oral formulations and extended-release injectable naltrexone.
Where does DeBinge provide implant-based treatment?
DeBinge implant-based treatment takes place in Nassau, The Bahamas. DeBinge does not operate naltrexone implant clinics in U.S. cities.
Should I withhold information about opioid use to protect my privacy?
No. Clinically important opioid use, methadone, buprenorphine, prescriptions and medical conditions should be disclosed to the treating clinician because incomplete information can make naltrexone treatment unsafe.
Further Reading
FDA: Medications for Opioid Use Disorder
FDA information on approved medications for opioid use disorder, including extended-release injectable naltrexone.
SAMHSA: Naltrexone
SAMHSA information about naltrexone, opioid-free preparation and the role of counselling in addiction treatment.
U.S. HHS: Health Information Privacy
General U.S. information about healthcare privacy and HIPAA protections for covered entities.
Compare Implant Programs
Use our structured framework to compare clinician qualifications, implant evidence, preparation, regulatory status, costs and aftercare.
Privacy law, healthcare regulation and professional confidentiality rules differ by jurisdiction and may change. Patients should confirm which rules apply to the specific clinical service and treatment location.
Prepared for Medical Review by Dr Fergus Law, BSc, MBChB, FRCPsych
Consultant Psychiatrist specialising in substance misuse and addiction psychiatry.
This page has been prepared as an educational resource and is awaiting formal clinical approval. Until that review is completed, it should not be represented as having been medically reviewed.
View Dr Fergus Law’s professional profile
Review status: Pending clinical approvalPrivacy Information Is Not Individual Legal or Medical Advice
This page explains general privacy, confidentiality and treatment-planning issues that patients may wish to discuss before receiving addiction treatment. It does not provide individual legal advice, determine which privacy law applies to a particular person or establish whether long-acting naltrexone is medically appropriate.
Do not withhold clinically important substance-use, medication or medical information solely for privacy reasons. Incomplete information can make treatment unsafe, particularly where opioid dependence, fentanyl exposure, methadone, buprenorphine or other medications are involved.
Suspected overdose, severe withdrawal, loss of consciousness, abnormal breathing or another medical emergency requires immediate local emergency assistance.